Silvan Tuerkcan
Stock Analyst at JMP Securities
(2.26)
# 2,695
Out of 4,918 analysts
166
Total ratings
41.42%
Success rate
-2.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $37.26 | +34.19% | 23 | Jul 29, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $70 → $12 | $2.89 | +315.22% | 6 | Jul 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $56.09 | +53.33% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $2.23 | +169.06% | 3 | Jun 25, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $6.83 | +119.62% | 3 | Jun 6, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $2.63 | +128.14% | 13 | May 29, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $4.04 | +48.51% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $11.05 | +81.00% | 12 | May 15, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $5.00 | +80.00% | 3 | May 15, 2025 | |
| VOR Vor Biopharma | Downgrades: Market Perform | $6 | $2.10 | +185.71% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $3.83 | +369.97% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $5.47 | +265.63% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.27 | +1,238.58% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $4.21 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.71 | +463.38% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $3.37 | +524.07% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.58 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $2.95 | +103.39% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $250.54 | +11.76% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $9.78 | +84.05% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.49 | - | 10 | Jan 19, 2023 |
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $37.26
Upside: +34.19%
Jasper Therapeutics
Jul 8, 2025
Maintains: Market Outperform
Price Target: $70 → $12
Current: $2.89
Upside: +315.22%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $56.09
Upside: +53.33%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $2.23
Upside: +169.06%
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $6.83
Upside: +119.62%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $2.63
Upside: +128.14%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $4.04
Upside: +48.51%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $11.05
Upside: +81.00%
Foghorn Therapeutics
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $5.00
Upside: +80.00%
Vor Biopharma
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $2.10
Upside: +185.71%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.83
Upside: +369.97%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $5.47
Upside: +265.63%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.27
Upside: +1,238.58%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $4.21
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.71
Upside: +463.38%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.37
Upside: +524.07%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.58
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $2.95
Upside: +103.39%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $250.54
Upside: +11.76%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $9.78
Upside: +84.05%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.49
Upside: -